[1] |
LEE NY, ROH MS, KIM SH, et al.The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with schizophrenia.[J].Int Clin Psychopharmacol, 2013, 28(2):71. doi: 10.1097/YIC.0b013e32835b99bd |
[2] |
VANCAMPFORT D, WAMPERS M, MITCHELL AJ, et al.A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls[J].World Psychiat, 2013, 12(3):240. doi: 10.1002/wps.20069 |
[3] |
LINDENMAYER JP, KHAN A, KAUSHIK S, et al.Relationship between metabolic syndrome and cognition in patients with schizophrenia[J].Schizophr Res, 2012, 142(1/3):171. |
[4] |
张爱慧.奥氮平治疗老年精神分裂症病人的临床疗效及对认知功能的改善作用[J].实用临床医药杂志, 2017, 21(1):154. |
[5] |
蒋鹏.阿立哌唑与奥氮平治疗精神分裂症病人的疗效和对糖脂代谢影响的对比研究[J].重庆医学, 2014, 43(1):96. |
[6] |
陈俊雄, 吴树跃, 林榕.齐拉西酮与奥氮平对老年精神分裂症病人糖脂代谢的影响及疗效[J].广东医学, 2012, 33(7):1006. doi: 10.3969/j.issn.1001-9448.2012.07.052 |
[7] |
VANCAMPFORT D, STUBBS B, MITCHELL AJ, et al.Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder:a systematic review and meta-analysis.[J].World Psychiat, 2015, 14(3):339. doi: 10.1002/wps.20252 |
[8] |
高慧, 姚培芬, 盛嘉玲, 等.长期服用奥氮平精神分裂症病人稳定期认知功能与代谢综合征的关系[J].临床精神医学杂志, 2017, 27(5):9. |
[9] |
姜涛, 魏琴, 侯琴琴, 等.奥氮平诱导性肥胖大鼠糖代谢紊乱及认知功能损伤研究[J].医学研究生学报, 2015, 28(3):264. doi: 10.3969/j.issn.1008-8199.2015.03.010 |
[10] |
买买提热厦提·吐尔逊, 马晓洁, 张文惠, 等.奥氮平诱导肥胖大鼠糖脂代谢紊乱对细胞因子和认知功能损伤的影响[J].中华行为医学与脑科学杂志, 2014, 23(7):591. doi: 10.3760/cma.j.issn.1674-6554.2014.07.005 |
[11] |
汪艳, 蔡丽伟, 张红星, 等.氟哌啶醇与奥氮平治疗精神分裂症疗效和安全性的随机对照研究[J].中国神经精神疾病杂志, 2012, 38(4):217. doi: 10.3969/j.issn.1002-0152.2012.04.005 |
[12] |
崔彦龙, 严保平, 孙秀丽, 等.氨磺必利与利培酮治疗阴性症状为主精神分裂症疗效及安全性对照研究[J].医学研究与教育, 2018, 35(6):49. |
[13] |
何书平, 仝冬晓, 司沛茹, 等.河南汉族人群精神分裂症病人线粒体ATP6基因9115、9185位点突变分析[J].郑州大学学报(医学版), 2018, 228(3):51. |